EP3846626A4 - Composition et méthodes pour la prévention ou la réduction de l'incidence d'accidents ischémiques transitoires - Google Patents

Composition et méthodes pour la prévention ou la réduction de l'incidence d'accidents ischémiques transitoires Download PDF

Info

Publication number
EP3846626A4
EP3846626A4 EP19856130.0A EP19856130A EP3846626A4 EP 3846626 A4 EP3846626 A4 EP 3846626A4 EP 19856130 A EP19856130 A EP 19856130A EP 3846626 A4 EP3846626 A4 EP 3846626A4
Authority
EP
European Patent Office
Prior art keywords
incidence
preventing
reducing
composition
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19856130.0A
Other languages
German (de)
English (en)
Other versions
EP3846626A1 (fr
Inventor
Zhigang Xiong
Roger Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morehouse School of Medicine Inc
Original Assignee
Morehouse School of Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/114,815 external-priority patent/US10603316B2/en
Application filed by Morehouse School of Medicine Inc filed Critical Morehouse School of Medicine Inc
Publication of EP3846626A1 publication Critical patent/EP3846626A1/fr
Publication of EP3846626A4 publication Critical patent/EP3846626A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19856130.0A 2018-08-28 2019-08-28 Composition et méthodes pour la prévention ou la réduction de l'incidence d'accidents ischémiques transitoires Pending EP3846626A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/114,815 US10603316B2 (en) 2013-08-21 2018-08-28 Composition and methods for preventing or reducing the incidence of transient ischemic attacks
PCT/US2019/048572 WO2020047097A1 (fr) 2018-08-28 2019-08-28 Composition et méthodes pour la prévention ou la réduction de l'incidence d'accidents ischémiques transitoires

Publications (2)

Publication Number Publication Date
EP3846626A1 EP3846626A1 (fr) 2021-07-14
EP3846626A4 true EP3846626A4 (fr) 2022-08-17

Family

ID=69645345

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19856130.0A Pending EP3846626A4 (fr) 2018-08-28 2019-08-28 Composition et méthodes pour la prévention ou la réduction de l'incidence d'accidents ischémiques transitoires

Country Status (3)

Country Link
EP (1) EP3846626A4 (fr)
CN (2) CN112888312A (fr)
WO (1) WO2020047097A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9629838B2 (en) * 2004-09-16 2017-04-25 Morehouse School Of Medicine Composition for reducing nervous system injury and method of making and use thereof
US8030442B2 (en) * 2004-09-16 2011-10-04 Morehouse School Of Medicine Treatment of injury to the brain by inhibition of acid sensing ion channels
CN101472589A (zh) * 2006-04-06 2009-07-01 先灵公司 用于治疗心血管疾病的含有凝血酶受体拮抗剂的组合物制剂之用途
US20080254036A1 (en) * 2007-04-13 2008-10-16 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
EP2471945A1 (fr) * 2010-12-30 2012-07-04 Siemens Healthcare Diagnostics Products GmbH Procédé de détermination d'inhibiteurs de coagulation
JP2016528283A (ja) * 2013-08-21 2016-09-15 モアハウス スクール オブ メディスンＭｏｒｅｈｏｕｓｅ Ｓｃｈｏｏｌ Ｏｆ Ｍｅｄｉｃｉｎｅ 神経系損傷を減少させるための組成物及びその製造方法及び使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
CN114712361A (zh) 2022-07-08
WO2020047097A1 (fr) 2020-03-05
EP3846626A1 (fr) 2021-07-14
CN112888312A (zh) 2021-06-01

Similar Documents

Publication Publication Date Title
EP3874030A4 (fr) Compositions et procédés pour l'ingénierie des lymphocytes t
EP3823673A4 (fr) Compositions anti-cd112r et procédés
EP3864152A4 (fr) Procédés et compositions pour éditer des arn
EP3808357A4 (fr) Composition et ses applications
EP3810109A4 (fr) Compositions et procédés d'inhibition de cd73
EP3720432A4 (fr) Composition et procédé pour la réduction de la réaction allergique
EP3801478A4 (fr) Méthodes et compositions pour la prévention ou le traitement de la calciphylaxie
EP3724293A4 (fr) Compositions d'asphalte et leurs procédés d'utilisation
EP3978468A4 (fr) Composé et composition
EP3814429A4 (fr) Compositions d'asphalte et procédés pour les former
EP3978106A4 (fr) Tensioactif et composition de tensioactif
EP3870210A4 (fr) Compositions et procédés de traitement ou de prévention de la fibrose
EP3675813A4 (fr) Méthode et composition destinées à prévenir et à traiter des infections virales
EP3810152A4 (fr) Méthodes et compositions de protection cellulaire
EP4017857A4 (fr) Inhibiteurs de mettl 16 et leurs utilisations
EP3972986A4 (fr) Procédés et compositions pour l'inhibition irréversible d'enzyme
EP3773579A4 (fr) Compositions et procédés pour inhiber la dihydroorotate déshydrogénase
EP3724331A4 (fr) Procédés et compositions pour l'amplification d'arnm
EP3846626A4 (fr) Composition et méthodes pour la prévention ou la réduction de l'incidence d'accidents ischémiques transitoires
EP3937950A4 (fr) Compositions topiques pour la protection thermique et leurs procédés de fabrication
EP3919612A4 (fr) Composition et son application
EP3853230A4 (fr) Inhibiteurs de cdpk1, compositions et procédés associés
EP3727382A4 (fr) Compositions et méthodes permettant de prévenir et de traiter des pathologies
EP3744801A4 (fr) Composition d'agent de revêtement, et procédé de revêtement de structure
EP3846625A4 (fr) Composition de tensioactif et son utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210323

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A01N0037180000

Ipc: A61K0031155000

A4 Supplementary search report drawn up and despatched

Effective date: 20220714

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/10 20060101ALI20220711BHEP

Ipc: A61K 38/17 20060101ALI20220711BHEP

Ipc: A61K 35/646 20150101ALI20220711BHEP

Ipc: A01N 37/18 20060101ALI20220711BHEP

Ipc: A61K 45/06 20060101ALI20220711BHEP

Ipc: A61K 9/00 20060101ALI20220711BHEP

Ipc: A61K 31/4965 20060101ALI20220711BHEP

Ipc: A61K 31/4418 20060101ALI20220711BHEP

Ipc: A61K 31/439 20060101ALI20220711BHEP

Ipc: A61K 31/40 20060101ALI20220711BHEP

Ipc: A61K 31/155 20060101AFI20220711BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230523

17Q First examination report despatched

Effective date: 20230616